Subscribe to RSS
DOI: 10.1055/a-2189-6053
Relevanz der Vitamin D-Messung in der Patientenbetreuung
Relevance of the Measurement of Vitamin D in Patient Care
Zusammenfassung
Vitamin D und seine Metaboliten sind für den Knochen- und Mineralstoffwechsel, aber auch für andere Organsysteme, von großer Bedeutung. Zur Diagnostik eines Vitamin D Mangels wird die Bestimmung des 25-hydroxyvitamin D im Serum oder Plasma verwendet. Allerdings sind die Messmethoden (Assays) nicht sehr gut standardisiert und anfällig für Störfaktoren. Überdies wird von vielen Methoden nicht nur das 25-hydroxyvitamin D erfasst, sondern auch andere Vitamin D-Metaboliten. Ein generelles Screening auf Vitamin D-Mangel wird für die allgemeine Bevölkerung nicht empfohlen, sondern nur für Risikogruppen und für ältere Menschen. Auch für Patienten mit Osteoporose wird die Messung von 25-hydroxyvitamin D nur bei V.a. Vitamin-D-Mangel und Osteomalazie empfohlen. Im Verlauf einer medikamentösen Behandlung mit Vitamin D kann bei V.a. Malabsorption oder anderen Problemen ein Monitoring von 25-hydroxyvitamin D im Therapieverlauf sinnvoll sein. Bei speziellen Fragestellung (z. B. Hypercalciämie) kann auch die Bestimmung von 1,25-dihydroxyvitamin D und 24,25-dihydroxyvitamin D notwendig sein.
ABSTRACT
Vitamin D and its metabolites are of great importance for bone and mineral metabolism and for other organs. The diagnosis of vitamin D deficiency is made by measuring 25-hydroxyvitamin D in serum or plasma. However, assay methodology is not very well standardized and may be influenced by interfering factors. Moreover, many assays do not detect only 25-hydroxyvitamin D but also other metabolites. A general screening for vitamin D deficiency in the population is not recommended, but only for people at risk and for the elderly. Accordingly, also for osteoporosis patients the measurement of 25-hydroxyvitamin D is only suggested in the case of suspected vitamin D deficiency and osteomalacia. During the course of vitamin D-treatment a monitoring of 25-hydroxyvitamin D may be useful if malabsorption or other problems are suspected. In case of special clinical situations such as hypercalcemia of unknown origin the measurement of 1,25- dihydroxyvitamin D and 24,25-dihydroxyvitamin D may be necessary.
Schlüsselwörter
Vitamin D - 25-OH-Vitamin D-Messung - Osteoporose - Osteomalazie - PatientenbetreuungPublication History
Received: 31 July 2023
Accepted: 10 October 2023
Article published online:
04 December 2023
© 2023. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
Literatur
- 1 Binkley N, Lappe J, Singh RJ. et al. Can vitamin D metabolite measurements facilitate a “treat-to-target” paradigm to guide vitamin D supplementation?. Osteoporos Int 2015; 26: 1655-1660
- 2 Bouillon R, Bikle D. Vitamin D Metabolism Revised: Fall of Dogmas. Journal of Bone and Mineral Research 2019; 34: 1985-1992
- 3 Chakhtoura M, Rahme M, Fuleihan GEH. Vitamin D Metabolism in Bariatric Surgery. Endocrinol Metab Clin North Am 2017; 46: 947-982
- 4 Chan LN, Neilson CH, Kirk EA. et al. Optimization of Vitamin D Status after Roux-en-Y Gastric Bypass Surgery in Obese Patients Living in Northern Climate. Obes Surg 2015; 25: 2321-2327
- 5 Chevalley T, Brandi ML, Cashman KD. et al. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clinical and Experimental Research 2022; 34: 2603-2623
- 6 Cummings SR, Rosen C. Vital Findings - A Decisive Verdict on Vitamin D Supplementation. N Engl J Med 2022; 387: 368-370
- 7 Dachverband deutschsprachiger osteologischer Fachgesellschaften (DVO). S3 – Leitlinie Osteoporose www.dv-osteologie.org
- 8 Delanaye P, Lanot A, Bouquegneau A. et al. Monitoring 25-OH and 1,25-OH vitamin D levels in hemodialysis patients after starting therapy: Does it make sense?. Clin Chim Acta 2023; 539: 50-54
- 9 Elsenberg EH, Boekel ET, Huijgen H. et al. Standardization of automated 25-hydroxyvitamin D assays: How successful is it ?. Clinical Biochemistry 2017; 50: 1126-1130
- 10 Favresse J, Schiettecatte J, Wolff F. et al. Two-site evaluation of the Roche Elecsys Vitamin D total III assay. Clin Chem Lab Med 2022; 60: 1598-1606
- 11 Giustina A, Adler RA, Binkley N. et al. Consensus statement from 2nd International Conference on Controversies in Vitamin D. Reviews in Endocrine and Metabolic Disorders 2020; 21: 89-116
- 12 Heijboer AC, Blankenstein MA, Kema IP. et al. Accuracy of 6 Routine 25-Hydroxyvitamin D Assays: Influence of Vitamin D Binding Protein Concentration. Clinical Chemistry 2012; 58: 543-548
- 13 Herrmann M, Farrell CJL, Pusceddu I. et al. Assessment of vitamin D status – a changing landscape. Clin Chem Lab Med 2017; 55: 3-26
- 14 Jemielita TO, Leonard MB, Baker J. et al. Association of 25-hydroxyvitamin D with areal and volumetric measures of bone mineral density and parathyroid hormone: impact of vitamin D-binding protein and its assays. Osteoporos Int 2016; 27: 617-626
- 15 Kaufmann M, Schlingmann KP, Berezin L. et al. Differential diagnosis of vitamin D-related hypercalcemia using serum vitamin D metabolite profiling. Journal of Bone and Mineral Research 2021; 36: 1340-1350
- 16 Makris K, Bhattoa HP, Cavalier E. et al. Recommendations on the measurement and the clinical use of vitamin D metabolites and vitamin D binding protein – A position paper from the IFCC Committee on bone metabolism. Clin Chim Acta 2021; 517: 171-197
- 17 McChesney C, Singer A, Duquette D. et al. Do not routinely test for vitamin D. BMJ 2022; 378: e070270
- 18 Peiris AN, Bailey BA, Manning T. et al. Are 25-Hydroxyvitamin D levels adequately monitored following evidence of Vitamin D insufficiency in veterans?. Military Medicine 2010; 175: 453-456
- 19 Pilz S, Theiler-Schwetz V, Pludowski P. et al. Hypercalcemia in Pregnancy Due to CYP24A1 Mutations: Case Report and Review of the Literature. Nutrients 2022; 14: 2518
- 20 Powe CE, Evans MK, Wenger J. et al. Vitamin D-binding protein and Vitamin D status of black Americans and white Americans. N Engl J Med 2013; 369: 1991-2000
- 21 Rizzoli R, Boonen S, Brandi ML. et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update for the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 2013; 29: 1-9
- 22 Rossini M, Gatti D, Viapiana O. et al. Short-Term Effects on Bone Turnover Markers of a Single High Dose of Oral Vitamin D3. J Clin Endocrinol Metab 2012; 97: E622-E626
- 23 Scharla SH, Lempert UG. Evaluation of an automated competitive protein-binding assay for 25-hydroxyvitamin D. Clin Lab 2016; 62: 1781-1786
- 24 Scharla SH. Pleiotrope Wirkung von Vitamin D mit Berücksichtigung von COVID-19. J Miner Stoffwechs Muskuloskelet Erkrank 2021; 28: 2-11
- 25 Scharla SH. Die Dauersequenz – Kalzium und Vitamin D. In: Thomasius F (Herausgeber) Sequenztherapie der Osteoporose – Theorie und moderne Praxiskonzepte. UNI-MED Verlag, Bremen; London, Boston: 2023. Seiten 64-68
- 26 Shah R, Licata A, Oyesiku NM. et al. Acromegaly as a cause of 1,25-dihydroxyvitamin D -dependent hypercalcemia: case reports and review of the literature. Pituitary 2012; 15: 17-22
- 27 Thacher TD. Evaluating the Evidence in Clinical Studies of Vitamin D in COVID-19. Nutrients 2022; 14: 464
- 28 Zittermann A, Berthold HK, Pilz S. The effect of vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. European Journal of Clinical Nutrition 2021; 75: 980-987
- 29 Zhang JT, Kwun SY, Benson KA. A case of severe 1,25-Dihydroxyvitamin D -Mediated Hypercalcemia due to a Granulomatous Disorder. J Clin Endocrinol Metab 2012; 97: 2597-2583